C4 Therapeutics (CCCC) Competitors $1.38 +0.03 (+1.84%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. MAZE, SIGA, ZVRA, SAGE, AMLX, PRTA, PRTC, ABVX, TRML, and PGENShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Prothena (PRTA), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Maze Therapeutics SIGA Technologies Zevra Therapeutics Sage Therapeutics Amylyx Pharmaceuticals Prothena PureTech Health ABIVAX Société Anonyme Tourmaline Bio Precigen C4 Therapeutics (NASDAQ:CCCC) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Does the MarketBeat Community prefer CCCC or MAZE? C4 Therapeutics received 21 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% Maze TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Which has higher valuation and earnings, CCCC or MAZE? Maze Therapeutics has higher revenue and earnings than C4 Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$39.78M2.47-$132.49M-$1.47-0.94Maze Therapeutics$167.50M2.68N/AN/AN/A Is CCCC or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. Maze Therapeutics' return on equity of 0.00% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Maze Therapeutics N/A N/A N/A Do insiders & institutionals have more ownership in CCCC or MAZE? 78.8% of C4 Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to CCCC or MAZE? In the previous week, C4 Therapeutics had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for C4 Therapeutics and 1 mentions for Maze Therapeutics. C4 Therapeutics' average media sentiment score of 0.97 beat Maze Therapeutics' score of -0.38 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CCCC or MAZE? C4 Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 766.43%. Maze Therapeutics has a consensus target price of $25.67, indicating a potential upside of 150.65%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 SummaryMaze Therapeutics beats C4 Therapeutics on 9 of the 15 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.35M$2.91B$5.31B$8.42BDividend YieldN/A1.68%5.21%4.10%P/E Ratio-0.8130.9526.7819.69Price / Sales2.47397.63386.97118.34Price / CashN/A168.6838.2534.62Price / Book0.343.206.744.50Net Income-$132.49M-$72.35M$3.23B$248.32M7 Day Performance0.36%3.87%1.49%-0.03%1 Month Performance-11.22%4.45%11.47%12.72%1 Year Performance-76.12%-27.42%16.57%7.38% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.5359 of 5 stars$1.39+1.8%$12.00+766.4%-76.4%$98.35M$39.78M-0.81150Gap UpMAZEMaze TherapeuticsN/A$10.13+5.3%$25.67+153.4%N/A$443.65M$167.50M0.00121Gap UpSIGASIGA Technologies1.1843 of 5 stars$5.94+4.9%N/A-18.9%$424.36M$138.72M4.9540ZVRAZevra Therapeutics3.2458 of 5 stars$7.75-1.5%$22.29+187.6%+87.4%$423.76M$23.61M-3.9320Analyst RevisionSAGESage Therapeutics3.955 of 5 stars$6.75+2.9%$8.81+30.6%-43.6%$410.79M$47.40M-1.02690Analyst DowngradeAMLXAmylyx Pharmaceuticals3.4619 of 5 stars$4.60-0.2%$9.67+110.1%+201.7%$409.79M$-1,272,000.00-1.20200PRTAProthena3.8645 of 5 stars$7.61+2.4%$51.71+579.6%-68.5%$409.62M$137.94M-3.31130Positive NewsHigh Trading VolumePRTCPureTech Health1.5192 of 5 stars$17.03+1.5%$45.00+164.3%-39.3%$408.92M$4.32M0.00100News CoverageGap UpABVXABIVAX Société Anonyme2.4584 of 5 stars$6.40-4.6%$34.00+431.3%-59.3%$405.88MN/A0.0061TRMLTourmaline Bio1.8547 of 5 stars$15.78+4.5%$49.33+212.6%+7.7%$405.31MN/A-5.6044PGENPrecigen3.4136 of 5 stars$1.37+3.0%$7.00+410.9%-5.0%$404.38M$3.93M-2.49190News CoverageAnalyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies Maze Therapeutics Competitors SIGA Technologies Competitors Zevra Therapeutics Competitors Sage Therapeutics Competitors Amylyx Pharmaceuticals Competitors Prothena Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors Tourmaline Bio Competitors Precigen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CCCC Stock Free CCCC Stock Alerts